A novel approach for the generation of human dendritic cells from blood monocytes in the absence of exogenous factors

Journal of Immunological Methods
Brian C Schanen, Donald R Drake

Abstract

Human dendritic cells (DCs) for research and clinical applications are typically derived from purified blood monocytes that are cultured in a cocktail of cytokines for a week or more. Because it has been suggested that these cytokine-derived DCs may be deficient in some important immunological functions and might not accurately represent antigen presenting cell (APC) populations found under normal conditions in vivo, there is an interest in developing methods that permit the derivation of DCs in a more physiologically relevant manner in vitro. Here, we describe a simple and reliable technique for generating large numbers of highly purified DCs that is based on a one-way migration of blood monocytes through a layer of human umbilical vein endothelial cells (HUVECs) that are cultured to confluency in the upper chamber of a Transwell device. The resultant APCs, harvested from the lower Transwell chamber, resemble other cultured DC populations in their expression of major histocompatibility (MHC) and costimulatory molecules, ability to phagocytose protein antigens and capacity to trigger primary antigen-specific T cell responses. This technique offers several advantages over the standard method of in vitro cytokine-driven DC develo...Continue Reading

References

Jun 1, 1983·Proceedings of the National Academy of Sciences of the United States of America·C J EdgellJ B Graham
Jul 1, 1994·The Journal of Experimental Medicine·N RomaniG Schuler
Mar 19, 1996·Proceedings of the National Academy of Sciences of the United States of America·L J Zhou, T F Tedder
Jun 17, 1998·Proceedings of the National Academy of Sciences of the United States of America·G J RandolphW A Muller
Jun 3, 2000·Annual Review of Immunology·J BanchereauK Palucka
Apr 9, 2001·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·M ThurnherL Höltl
Nov 7, 2001·The Journal of Experimental Medicine·W A Muller
Jul 20, 2002·Veterinary Immunology and Immunopathology·Elida M BautistaWilliam T Golde
Feb 11, 2003·Journal of Neuroimmunology·Rosanne SéguinJack P Antel
Jul 2, 2003·Experimental and Molecular Pathology·Smaroula DilioglouRobert E Lewis
Jan 15, 2004·Proceedings of the National Academy of Sciences of the United States of America·Mark J MillerIan Parker
Mar 9, 2004·Experimental Hematology·Geneviève Despars, Helen C O'Neill
Apr 7, 2007·Immunobiology·Nathalie SchmittNicole Israël
Aug 21, 2007·European Journal of Immunology·Dennis KirchhoffAlexander Scheffold

❮ Previous
Next ❯

Citations

Nov 21, 2009·Journal of Immunological Methods·Janice M MoserDonald R Drake
Aug 11, 2020·International Journal of Pharmaceutics: X·Marie GarinotJean Haensler

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Anthrax

Anthrax toxin, comprising protective antigen, lethal factor, and oedema factor, is the major virulence factor of Bacillus anthracis, an agent that causes high mortality in humans and animals. Here is the latest research on Anthrax.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Anthrax Vaccines

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Anthrax Vaccines (ASM)

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.